| Title: | Contact urticaria and related conditions: clinical review |
|---|
| Authors: | ID Bizjak, Mojca, Univerzitetna klinika za pljučne bolezni in alergijo Golnik (Corresponding author)
ID Aerts, Olivier (Author)
ID Pesqué, David (Author)
ID Munoz, Melba (Author)
ID Asero, Riccardo (Author)
ID Gonçalo, Margarida (Author)
ID Rustemeyer, Thomas (Author)
ID Košnik, Mitja, Univerzitetna klinika za pljučne bolezni in alergijo Golnik (Corresponding author)
ID Kačar, Mark, Univerzitetna klinika za pljučne bolezni in alergijo Golnik (Author)
ID Giménez-Arnau, Ana M. (Author) |
|---|
| Files: |  URL - Source URL, visit https://onlinelibrary.wiley.com/doi/epdf/10.1111/cod.14794
 PDF - Presentation file, download (737,36 KB)
MD5: ED11AAFE98A1BA15DE6D23BDA554A107
|
|---|
| Language: | English |
|---|
| Typology: | 1.02 - Review Article |
|---|
| Organization: |  UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
|
|---|
| Abstract: | Contact urticaria (CoU) is an immediate contact reaction occurring within minutes to an hour after exposure to specific proteins or chemicals. CoU is categorised into non-immunologic (NI-CoU) and immunologic (I-CoU) types, with I-CoU potentially leading to anaphylaxis. Both forms of CoU can be associated with protein contact dermatitis and the CoU syndrome. Patients with I-CoU may also have other type I (immediate) allergic diseases, such as allergic conjunctivitis, rhinitis, asthma or food allergy. This review provides a detailed overview of CoU and related conditions, focusing on triggers, diagnostic methods and management strategies. NI-CoU is typically triggered by low molecular weight chemicals, while I-CoU involves IgE-mediated hypersensitivity to both high molecular weight proteins and low molecular weight chemicals. Early diagnosis is crucial, though CoU is often underrecognized. The diagnostic approach includes a thorough medical history, physical examination, evaluation of photographs, (non)invasive skin tests and in vitro assessments. Management strategies prioritise trigger avoidance and pharmacological treatments when avoidance is not fully possible. For I-CoU, second-generation H1-antihistamines are the first-line treatment. Severe cases of I-CoU may benefit from anti-IgE therapy (omalizumab). Patients at risk of anaphylaxis should carry an adrenaline auto-injector and wear a medical alert bracelet. |
|---|
| Keywords: | inducible urticaria, occupational urticaria, protein contact dermatitis |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Submitted for review: | 01.11.2024 |
|---|
| Article acceptance date: | 06.03.2025 |
|---|
| Publication date: | 01.08.2025 |
|---|
| Year of publishing: | 2025 |
|---|
| Number of pages: | str. 87-107 |
|---|
| Numbering: | Vol. 93, issue 2 |
|---|
| PID: | 20.500.12556/DiRROS-22929  |
|---|
| UDC: | 616.5-002:616.97 |
|---|
| ISSN on article: | 1600-0536 |
|---|
| DOI: | 10.1111/cod.14794 |
|---|
| COBISS.SI-ID: | 232153859 |
|---|
| Copyright: | © 2025 The Author(s). Contact Dermatitis published by John Wiley & Sons Ltd. |
|---|
| Note: | Nasl. z nasl. zaslona;
Avtorji iz Slovenije: Mojca Bizjak, Mitja Košnik, Mark Kačar;
Opis vira z dne 10. 4. 2025;
|
|---|
| Publication date in DiRROS: | 09.07.2025 |
|---|
| Views: | 423 |
|---|
| Downloads: | 284 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
